tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Hold Rating for Adaptimmune Therapeutics Amid Strategic Progress and Financial Uncertainties
PremiumRatingsHold Rating for Adaptimmune Therapeutics Amid Strategic Progress and Financial Uncertainties
2M ago
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
2M ago
Adaptimmune’s Earnings Call: Success Amid Financial Concerns
Premium
Company Announcements
Adaptimmune’s Earnings Call: Success Amid Financial Concerns
2M ago
Adaptimmune price target lowered to 46c from $1 at Barclays
PremiumThe FlyAdaptimmune price target lowered to 46c from $1 at Barclays
2M ago
Adaptimmune Therapeutics Reports Q1 2025 Earnings
Premium
Company Announcements
Adaptimmune Therapeutics Reports Q1 2025 Earnings
2M ago
ADAP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
ADAP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
Adaptimmune Therapeutics: Balancing Positive Momentum with Strategic Pauses – A Hold Rating Analysis
PremiumRatingsAdaptimmune Therapeutics: Balancing Positive Momentum with Strategic Pauses – A Hold Rating Analysis
4M ago
Adaptimmune price target lowered to $1.75 from $3 at Guggenheim
Premium
The Fly
Adaptimmune price target lowered to $1.75 from $3 at Guggenheim
4M ago
Adaptimmune’s Earnings Call: TECELRA Success and Future Outlook
Premium
Company Announcements
Adaptimmune’s Earnings Call: TECELRA Success and Future Outlook
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100